Background: The correlation between hepatitis B, C viruses (HBV, HCV) and B cell non-Hodgkin’s Lymphoma (B-NHL) and reducing mortality have been studied extensively worldwide Objective: In this study, we aimed to determine the prevalence of HBsAg and anti-HCV positive cases among B-NHL patients and its influence on the survival rate of these patients (on ≤12 months). Materials and Methods: We have done a retrospective analysis on patients who aged over 20 years and newly diagnosed at the Hematology Center of the First State Hospital between 2015-2018. The patients’ information was collected according the study ethics. We divided the patients into 2 groups, survival rate less than 12 months (≤12 months) and survival rate more than 13 months (≥13 months), and compared them regarding age, gender, seroprevalence, and Ann-Arbor stage. Results: Overall, 226 patients (107 males and 119 females with average 54.4) were enrolled in the study. There were 15% HBsAg positive and 41,6% anti-HCV positive cases, while Baatarkhuu et al. (2005) reported (11.8%, 15.6%; p=0.160, p<0.00001) and Bekhbold et al. (2013) reported (11.1%, 10.6%; p=0.055, p<0.00001) in apparently healthy population. Moreover, anti-HCV positive cases among B-NHL patients were higher (p<0.00001) than those (27%) among hepatocellular carcinoma (HCC) patients and same (p=0.404) with those (39%) among liver cirrhosis patients in Mongolia (Bolormaa et al., 2009). Furthermore, 72.0% of all subjects in III-IV stages was accounted for HBsAg, anti-HCV positive group which had ≤12 months, while 52.1% of them was accounted for HBsAg, anti-HCV positive group which had ≥13 months and was statistical significantly lower (p=0.02). Conclusion Anti-HCV and HBsAg positive cases might contribute to survival rate with the B-NHL patients diagnosed at the III-IV stages. HCV prevalence among B-NHL subjects was significantly higher than that among the general population prevalence and was same with anti-HCV positive prevalence among the HCC.

Introduction: According to the World Health Organization (WHO) in 2020, brain and central nervous system (CNS) cancers account for 2% of all newly diagnosed cancers in the world and 1.5% in Mongolia. Approximately 85-90% of all brain and other CNS tumors were diagnosed primary brain tumor. In 2019, the average 5 year survival probability was 50% for other cancers and 11% for the primary brain tumors. There were 28 patients with primary brain tumor and 33 relatively healthy individuals in our study. Goal: To study the diagnostic value of serum aquaporin-4 and glial fibrous acidic protein in the diagnosis of primary brain cancer Material and Methods: The Department of Neurosurgery at Third central hospital included 28 patients with primary brain cancer and 33 relatively healthy people. The study was conducted under the permission of the Medical Ethics Review Committee of the Ministry of Health on June 19, 2019 №119. Serum aquaporin-4 and glial fibrous acidic protein content was determined by the ELISA kits method using the human aquaporin-4 and glial fibrous acid protein test kit of the Chinese company “Sanlong”. The level is assumed to be true if the p value is less than 0.05. Results Mean age of the all participants was 42.9±16.5, 64% female and 36% male. Serum aquaporin-4 protein levels were 175.71±13.3 pg/ml and serum glial fibrilliary acidic protein levels were 2.682±0.218 ng/ml in patient with primary brain tumor. Serum aquaporin-4 protein and glial fibrilliary acidic protein levels were statistically significant high (p<0.001) in patient with primary brain tumor. Serum aquaporin-4 protein and glial fibrilliary acidic protein level differences were statistically significant (p<0.05) in benign and malignant tumor. There was no statistically significant correlation between serum aquaporin-4 and glial fibrillary acidic protein level and primary brain tumor grade.

Background: Chemotherapy-related acute exacerbation or hepatitis flares related to HCV positive B cell non-Hodgkin’s lymphoma (B-NHL) is one of the significant clinical issues Material and Method: We studied anti-HCV incidences among patients newly diagnosed with B-NHL, from 2015 to 2018. Survey data were collecting from medical history, electronic medical record system of First Central Hospital was acquired and collected according to the research ethics (approved by Ethics Committee of Ministry of Health, No.4 on June 19, 2017). Also, cases of chemotherapy-related acute exacerbation (AE) for HCV-RNA positive cases were studied. Student’s t-test or nonparametric statistics were utilized to test for statistically significant differences in continuous variables, whereas the chi-square or Fisher’s exact test was used for categorical variables. p<0.05 was considered statistically significant. Results: The study showed that 39.5% of 233 cases with B-NHL are anti-HCV positive. Anti-HCV positive prevalence among B-NHL subjects was significantly higher compared to the general population. Chemotherapy-related AE occurred in 21.05% for the anti-HCV positive group and 36.36% for HCV-RNA positive group. Furthermore, before chemotherapy alanine aminotransferase (ALT) median was 15.2 for the group without AE, whereas it was 48.2 for the group with AE (p<0.01). Conclusions Our study showed that the prevalence of anti-HCV positive among B-NHL patients was significantly higher than the general population prevalence. For all cases of AE, HCV-RNA was positive, and these patients were treated with only chemotherapy without any anti-viral treatment. Anti-viral therapy needs to be introduced urgently to prevent AE since liver fibrosis is aggravated quickly after AE.